Robin M Murray Selected Research

Polytetrafluoroethylene (Teflon)

1/2022	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study.
1/2022	Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI).
12/2021	Across the continuum: Associations between (fluctuations in) momentary self-esteem and psychotic experiences.
11/2021	Elucidating negative symptoms in the daily life of individuals in the early stages of psychosis.
10/2021	Structural Covariance of Cortical Gyrification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses.
10/2021	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study.
10/2021	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study.
10/2021	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study.
9/2021	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls.
6/2021	First-episode Psychosis and Migration in Italy: Results from a Study in the Italian Mental Health Services (Pep-Ita Study).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robin M Murray Research Topics

Disease

126	Psychotic Disorders (Schizoaffective Disorder) 04/2022 - 03/2004
75	Schizophrenia (Dementia Praecox) 05/2022 - 07/2002
11	Substance-Related Disorders (Drug Abuse) 01/2022 - 08/2004
10	Mental Disorders (Mental Disorder) 01/2022 - 07/2005
8	Bipolar Disorder (Manic Depressive Psychosis) 01/2022 - 10/2010
5	Cognitive Dysfunction 01/2019 - 01/2013
5	Paranoid Disorders (Paranoia) 01/2018 - 01/2013
4	Psychotic Affective Disorders 01/2022 - 01/2009
3	Treatment-Resistant Schizophrenia 01/2021 - 11/2012
2	Neurodevelopmental Disorders 01/2022 - 01/2021
2	Genetic Risk Score 01/2022 - 01/2021
2	Anhedonia 11/2021 - 02/2018
2	Hypersensitivity (Allergy) 01/2021 - 09/2014
2	Mania (Manias) 01/2020 - 12/2004
2	Inflammation (Inflammations) 01/2019 - 12/2011
2	Mood Disorders (Mood Disorder) 01/2018 - 03/2006
2	Asphyxia (Suffocation) 01/2017 - 07/2002
2	Hallucinations (Hallucination) 05/2014 - 08/2010
1	Major Depressive Disorder (Major Depressive Disorders) 01/2022
1	Dehydration (Water Stress) 01/2022
1	Tardive Dyskinesia 01/2021
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2020
1	Infections 01/2020
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2020
1	Obesity 12/2019
1	Tobacco Use Disorder (Nicotine Dependence) 06/2019
1	Disease Progression 01/2019
1	Glioma (Gliomas) 01/2018
1	Brain Injuries (Brain Injury) 11/2017
1	Weight Gain 11/2017
1	Hyperprolactinemia 11/2017
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/2017
1	Hypoxia (Hypoxemia) 01/2017

Drug/Important Bio-Agent (IBA)

53	Polytetrafluoroethylene (Teflon)FDA Link 01/2022 - 09/2007
30	Antipsychotic Agents (Antipsychotics)IBA 03/2022 - 04/2005
23	Dopamine (Intropin)FDA LinkGeneric 01/2019 - 10/2002
17	Biological ProductsIBA 01/2022 - 03/2006
9	Pharmaceutical PreparationsIBA 01/2021 - 03/2004
8	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2009
8	Dronabinol (THC)FDA LinkGeneric 01/2020 - 08/2010
7	Hydrocortisone (Cortisol)FDA LinkGeneric 04/2022 - 02/2010
6	Clozapine (Clozaril)FDA LinkGeneric 01/2021 - 02/2004
5	insulin receptor-related receptor (IRR)IBA 01/2021 - 03/2006
5	ProlactinIBA 11/2017 - 06/2005
5	Brain-Derived Neurotrophic Factor (BDNF)IBA 10/2014 - 04/2005
4	Glucose (Dextrose)FDA LinkGeneric 12/2019 - 02/2004
4	Indicators and Reagents (Reagents)IBA 01/2019 - 04/2008
4	AmphetaminesIBA 10/2013 - 05/2009
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2022 - 01/2018
3	EndocannabinoidsIBA 03/2022 - 08/2010
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 12/2011
3	Amphetamine (Amfetamine)FDA LinkGeneric 01/2022 - 01/2014
3	CannabidiolIBA 01/2020 - 10/2016
3	Cocaine (Cocaine HCl)IBA 01/2018 - 03/2006
3	Dihydroxyphenylalanine (Dopa)IBA 11/2017 - 12/2011
3	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 03/2009 - 10/2006
3	Methamphetamine (Desoxyn)FDA LinkGeneric 07/2005 - 08/2004
2	CannabinoidsIBA 03/2022 - 10/2016
2	Dihydrotachysterol (AT 10)IBA 02/2021 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2018
2	Nicotine FDA Link 06/2019 - 07/2013
2	Vitamin D FDA LinkGeneric 01/2019 - 11/2013
2	AntibodiesIBA 01/2018 - 10/2017
2	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2018 - 10/2017
2	Dopamine Receptors (Dopamine Receptor)IBA 09/2015 - 12/2004
2	N 30IBA 09/2015 - 01/2008
2	Illicit Drugs (Recreational Drugs)IBA 03/2015 - 05/2011
2	Protons (Proton)IBA 11/2014 - 12/2007
2	Glutamic Acid (Glutamate)FDA Link 11/2014 - 03/2014
2	Lysergic Acid Diethylamide (LSD)IBA 10/2013 - 01/2011
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 11/2009 - 03/2006
2	3' Untranslated Regions (3' UTR)IBA 11/2009 - 08/2009
2	Proline Oxidase (Proline Dehydrogenase)IBA 09/2007 - 08/2004
1	Silver Sulfadiazine (SSD)FDA LinkGeneric 01/2022
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2022
1	Caffeine (No Doz)FDA LinkGeneric 01/2022
1	Sp4 Transcription FactorIBA 01/2022
1	Unithiol (DMPS)IBA 01/2021
1	Complement C4 (Complement Component 4)IBA 01/2020
1	LipidsIBA 01/2019
1	C-Reactive ProteinIBA 01/2019
1	hydroxide ionIBA 01/2019
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2019
1	Neurotransmitter Agents (Neurotransmitter)IBA 04/2018
1	Immunoglobulin G (IgG)IBA 02/2018
1	imidazole mustard (BIC)IBA 01/2018
1	Leucine (L-Leucine)FDA Link 01/2018
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 10/2017
1	AutoantibodiesIBA 10/2017
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2017
1	Histones (Histone)IBA 04/2016
1	BuffersIBA 10/2015
1	SmokeIBA 01/2015

Therapy/Procedure

3	Therapeutics 10/2013 - 12/2006
2	Length of Stay 02/2021 - 01/2020
2	Cesarean Section (Caesarean Section) 01/2017 - 07/2002
1	Secondary Prevention 01/2021
1	Treatment Delay 01/2020
1	Aftercare (After-Treatment) 01/2017
1	Intravenous Administration 03/2015